Granted Patent
B2
US 12,616,713 · App. 18/157,510 · Granted May 5, 2026
Methods for enhancing vascular density
Inventors:
Lindsay Edward Wu (Coogee, AU); David Andrew Sinclair (Chestnut Hill, MA); Abhirup Das (Eastlakes, AU)
Assignee:
Metro International Biotech, LLC
A61K31/7084A61K9/0053A61K31/706A61K33/04A61P9/14C12N15/1137C12N15/87C12N2310/14C12N2310/141C12N2710/10043C12N2740/15043
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to methods of increasing vascular density and/or blood flow in tissue of a subject, and to increasing exercise capacity of a subject, the methods include administering to a subject an effective amount of an agent that elevates SIRTI activity in endothelial cells of the subject, the invention further includes administering an NAD+ agonist or NAD+ precursor to a subject to increase vascular density and/or blood flow. The invention includes compositions comprising the said agent.
Claims (25)
1 . A method of treating hemorrhage in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising nicotinic acid mononucleotide (NaMN).
2 . The method of claim 1 , wherein the pharmaceutical composition is administered orally.
3 . The method of claim 1 , wherein the NaMN is in crystalline form.
4 . The method of claim 1 , wherein the pharmaceutical composition is in the form of a tablet, a troche, a lozenge, a dispersible powder or granule, a hard capsule.
5 . The method of claim 1 , wherein the pharmaceutical composition further comprises GYY4137, sodium hydrosulfide, or pharmaceutically acceptable salts thereof.
6 . The method of claim 1 , wherein the pharmaceutical composition is in the form of a tablet, a troche, a lozenge, an aqueous or oily suspension, a dispersible powder or granule, an emulsion, a hard or soft capsule, or a syrup or elixir.
7 . The method of claim 1 , wherein the pharmaceutical composition is in the form of a sterile injectable aqueous suspension, or a sterile injectable oleaginous suspension, or a sterile injectable aqueous solution, or a sterile injectable non-aqueous solution, or a sterile injectable non-aqueous suspension.
8 . The method of claim 7 , wherein the pharmaceutical composition further comprises a diluent or solvent selected from water, Ringer's solution, isotonic sodium chloride solution, oleic acid, and 1,3-butanediol.
9 . The method of claim 7 , wherein the pharmaceutical composition is administered in the form of a liposome.
10 . The method of claim 9 , wherein the liposome comprises phospholipid or phosphatidyl choline.
11 . The method of claim 1 , wherein said composition is adapted for administration by infusion.
12 . The method of claim 1 , wherein said composition is a sterile injectable aqueous solution.
13 . A method of treating hemorrhage in a subject in need thereof, the method comprising administering to the subject an effective amount of nicotinic acid mononucleotide (NaMN) in a sterile injectable aqueous solution by infusion.
14 . A method of treating ulcers in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising nicotinic acid mononucleotide (NaMN).
15 . The method of claim 14 , wherein the pharmaceutical composition is administered orally.
16 . The method of claim 14 , wherein the NaMN is in crystalline form.
17 . The method of claim 16 , wherein the pharmaceutical composition is formulated as one or more tablets, a troches, a lozenges, a dispersible powder or granules, or hard capsules.
18 . The method of claim 14 , wherein the pharmaceutical composition further comprises GYY4137, sodium hydrosulfide, or pharmaceutically acceptable salts thereof.
19 . The method of claim 14 , wherein the pharmaceutical composition is formulated as an aqueous or oily suspension, an emulsion, a dispersible powder or granules, a syrup or elixir, or one or more tablets, troches, lozenges, or hard or soft capsules.
20 . The method of claim 14 , wherein the pharmaceutical composition is a sterile injectable aqueous suspension, a sterile injectable oleaginous suspension, a sterile injectable aqueous solution, a sterile injectable non-aqueous solution, or a sterile injectable non-aqueous suspension.
21 . The method of claim 20 , wherein the pharmaceutical composition further comprises a diluent or solvent selected from water, Ringer's solution, isotonic sodium chloride solution, oleic acid, and 1,3-butanediol.
22 . The method of claim 20 , wherein the pharmaceutical composition comprises a liposome.
23 . The method of claim 22 , wherein the liposome comprises a phospholipid or phosphatidyl choline.
24 . The method of claim 14 , wherein said composition is administered by infusion.
25 . The method of claim 20 , wherein said composition is a sterile injectable aqueous solution.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 8, 2024
From: WU, LINDSAY EDWARD; SINCLAIR, DAVID ANDREW; DAS, ABHIRUP
To: NEWSOUTH INNOVATIONS PTY LTD
Reel/Frame 067348/0798 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 3, 2024
From: NEWSOUTH INNOVATIONS PTY LTD
To: METRO BIOTECH NSW PTY LTD
Reel/Frame 067311/0746 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 3, 2024
From: METRO BIOTECH NSW PTY LTD
To: METRO INTERNATIONAL BIOTECH, LLC
Reel/Frame 067311/0855 →
Priority Claims (1)
AU 2016905310
· Dec 21, 2016
· national
Continuity (2)
Continuation
16471653
References Cited (400)
US 3201389A
· Fujimoto et al.
· 1965
[cited by applicant]
US 3451997A
· Fujimoto et al.
· 1969
[cited by applicant]
US 4411995A
· Whitesides et al.
· 1983
[cited by applicant]
US 7560442B2
· Susilo
· 2009
[cited by applicant]
US 7776326B2
· Milbrandt et al.
· 2010
[cited by applicant]
US 7977049B2
· Sinclair et al.
· 2011
[cited by applicant]
US 8481711B2
· Kaminishi et al.
· 2013
[cited by applicant]
US 9169209B2
· Bair et al.
· 2015
[cited by applicant]
US 9295688B2
· Milbrandt et al.
· 2016
[cited by applicant]
US 9458172B2
· Bair et al.
· 2016
[cited by applicant]
US 9676721B2
· Bair et al.
· 2017
[cited by applicant]
US 9822129B2
· Bair et al.
· 2017
[cited by applicant]
US 9855289B2
· Normington et al.
· 2018
[cited by applicant]
US 9861651B2
· Brown et al.
· 2018
[cited by applicant]
US 9919003B2
· Normington et al.
· 2018
[cited by applicant]
US 9975915B1
· Migaud et al.
· 2018
[cited by applicant]
US 20040224039A1
· Brucker
· 2004
[cited by applicant]
US 20070149466A1
· Milburn et al.
· 2007
[cited by applicant]
US 20080318892A1
· Pickering et al.
· 2008
[cited by applicant]
US 20100047177A1
· Milbrandt et al.
· 2010
[cited by applicant]
US 20120107888A1
· Schmalisch et al.
· 2012
[cited by applicant]
US 20120328526A1
· Kristian
· 2012
[cited by applicant]
US 20130273034A1
· Bair et al.
· 2013
[cited by applicant]
US 20140221319A1
· Sinclair et al.
· 2014
[cited by applicant]
US 20140294805A1
· Bair et al.
· 2014
[cited by applicant]
US 20150258052A1
· Evans et al.
· 2015
[cited by applicant]
US 20160287621A1
· Sinclair et al.
· 2016
[cited by applicant]
US 20160355514A1
· Bair et al.
· 2016
[cited by applicant]
US 20160355539A1
· Migaud
· 2016
[cited by examiner]
US 20170182076A1
· Alvarez et al.
· 2017
[cited by applicant]
US 20170216262A1
· Bair et al.
· 2017
[cited by applicant]
US 20180051253A1
· Chen
· 2018
[cited by applicant]
US 20190328761A1
· Wu et al.
· 2019
[cited by applicant]
US 20200368198A1
· Wu et al.
· 2020
[cited by applicant]
US 20210030908A1
· Mason
· 2021
[cited by applicant]
US 20220098229A1
· Livingston et al.
· 2022
[cited by applicant]
US 20230210746A1
· Bermond et al.
· 2023
[cited by applicant]
US 20240109932A1
· Kremsky et al.
· 2024
[cited by applicant]
CN 101497638A
· 2009
[cited by applicant]
CN 101601679B
· 2011
[cited by applicant]
CN 102876759A
· 2013
[cited by applicant]
CN 104367587B
· 2018
[cited by applicant]
JP S4112737B2
· 1966
[cited by applicant]
JP S4115179B2
· 1996
[cited by applicant]
JP 2007063167A
· 2007
[cited by examiner]
JP 2008501343A
· 2008
[cited by applicant]
WO WO2006072809A2
· 2006
[cited by applicant]
WO WO2006094235A1
· 2006
[cited by examiner]
WO WO2007124447A2
· 2007
[cited by examiner]
WO WO2010135520A1
· 2010
[cited by applicant]
WO 2011130595A2
· 2011
[cited by applicant]
WO WO2012004917A1
· 2012
[cited by applicant]
WO WO2012031196A1
· 2012
[cited by applicant]
WO WO2012031197A1
· 2012
[cited by applicant]
WO WO2012031199A1
· 2012
[cited by applicant]
WO WO2012094343A1
· 2012
[cited by applicant]
WO 2012114204A2
· 2012
[cited by applicant]
WO WO2012150952A1
· 2012
[cited by applicant]
WO WO2013085555A2
· 2013
[cited by applicant]
WO WO2013127266A1
· 2013
[cited by applicant]
WO WO2013127267A1
· 2013
[cited by applicant]
WO WO2013127268A1
· 2013
[cited by applicant]
WO WO2013127269A1
· 2013
[cited by applicant]
WO WO2013130943A1
· 2013
[cited by applicant]
WO 2014059034A2
· 2014
[cited by applicant]
WO WO2014074715A1
· 2014
[cited by applicant]
WO WO2014111906A1
· 2014
[cited by applicant]
WO WO2014146044A1
· 2014
[cited by applicant]
WO WO2015014722A1
· 2015
[cited by applicant]
WO WO2015069860A1
· 2015
[cited by applicant]
WO WO2015073576A1
· 2015
[cited by applicant]
WO WO2015070280A1
· 2015
[cited by examiner]
WO WO2015138969A1
· 2015
[cited by applicant]
WO 2015187649A1
· 2015
[cited by applicant]
WO WO2015186068A1
· 2015
[cited by applicant]
WO WO2016014927A2
· 2016
[cited by applicant]
WO 2016086088A2
· 2016
[cited by applicant]
WO WO2016086860A1
· 2016
[cited by applicant]
WO WO2016093515A1
· 2016
[cited by examiner]
WO WO2016144660A1
· 2016
[cited by applicant]
WO WO2016196941A1
· 2016
[cited by applicant]
WO WO2016210232A1
· 2016
[cited by applicant]
WO WO2017022768A1
· 2017
[cited by applicant]
WO WO2017059249A1
· 2017
[cited by applicant]
WO WO2017062311A1
· 2017
[cited by applicant]
WO WO2017079195A1
· 2017
[cited by applicant]
WO WO2017110317A1
· 2017
[cited by applicant]
WO WO2017114796A1
· 2017
[cited by applicant]
WO WO2017145151A1
· 2017
[cited by applicant]
WO WO2017161165A1
· 2017
[cited by applicant]
WO WO2017185549A1
· 2017
[cited by applicant]
WO WO2017218580A1
· 2017
[cited by applicant]
WO WO2018023205A1
· 2018
[cited by applicant]
WO WO2018023207A1
· 2018
[cited by applicant]
WO WO2018023208A1
· 2018
[cited by applicant]
WO WO2018023209A1
· 2018
[cited by applicant]
WO WO2018023210A1
· 2018
[cited by applicant]
WO WO2018047715A1
· 2018
[cited by applicant]
WO WO2018047716A1
· 2018
[cited by applicant]
WO WO2018052019A1
· 2018
[cited by applicant]
WO WO2018052020A1
· 2018
[cited by applicant]
WO WO2018089830A1
· 2018
[cited by applicant]
WO WO2018120069A1
· 2018
[cited by applicant]
WO WO2018132833A1
· 2018
[cited by applicant]
WO WO2018143258A1
· 2018
[cited by applicant]
WO WO2019152416A1
· 2019
[cited by applicant]
WO WO2020072497A1
· 2020
[cited by applicant]
WO WO2020197882A1
· 2020
[cited by applicant]
WO WO2022251491A1
· 2022
[cited by applicant]
“Extended European Search Report corresponding to European Application No. 17883855.3 dated Dec. 15, 2020”.
[cited by applicant]
“Non-antioxidant function of resveratrol”, Vitamins 90:286-289 (2016).
[cited by applicant]
“Office Action corresponding to Chinese Application No. 20178006403.4 issued Dec. 29, 2022”.
[cited by applicant]
“Office Action corresponding to Chinese Application No. 201780086403.4 dated Apr. 6, 2022”.
[cited by applicant]
“Office Action corresponding to Japanese Application No. 2019-533084 dated Jun. 27, 2022”.
[cited by applicant]
“Office Action corresponding to Japanese Application No. 2019-533084 dated Mar. 30, 2023”.
[cited by applicant]
“Office Action corresponding to Japanese Application No. 2019-533084 dated Oct. 27, 2021”.
[cited by applicant]
“Office Action corresponding to Korean Application No. 10-2019-7021500 issued Feb. 28, 2023”.
[cited by applicant]
Chung, Sangwoon , et al., “Regulation of SIRT1 in cellular functions: Role of polyphenols”, Archives of Biochemistry and Biophysics 501(1):79-90 (May 5, 2010).
[cited by applicant]
Das, A , et al., “Nicotinamide mononucleotide, an NAD+ precursor, reverses age-associated decline in exercise capacity by increasing skeletal muscle capillary density in a Sirt1-dependent manner”, AuPS(Australian Physio…
[cited by applicant]
Fan, Weiwei , et al., “Exercise Mimetics: Impact on Health and Performance”, Cell Metabolism 25:242-247 (Feb. 7, 2017).
[cited by applicant]
Hart, Nikolett , et al., “Resveratrol enhances exercise training responses in rats selectively bred for high running performace”, Food and Chemical Toxicology 61:53-59 (2013).
[cited by applicant]
Imai, Shin-Ichiro , et al., “NAD+ and Sirtuins in Aging and Disease”, Trends Cell Biol 24(8):464-471 (Aug. 2014).
[cited by applicant]
Koltai, Eric , et al., “Exercise alters SIRT1, SIRT6, NAD and NAMPT levels in skeletal muscle of aged rats”, Mechanisms of Ageing and Development 131(1):21-28 (Nov. 12, 2009).
[cited by applicant]
Novelle, Marta G, et al., “Resveratrol supplementation: Where are we now and where should we go?”, Ageing Research Reviews 21:1-15 (2015).
[cited by applicant]
Rechsteiner, Martin , et al., “The Biosynthesis and Turnover of Nicotinamide Adenine Dinucleotide in Enucleated Culture Cells”, The Journal of Cellular Physiology 84(3):409-421 (Dec. 1, 1974).
[cited by applicant]
Verdin, Eric , et al., “NAD+ in aging, metabolism, and neurodegeneration”, Science 350(6265):1208-1213 (Dec. 4, 2015).
[cited by applicant]
Vinciguerra, Manlio , et al., “SirT1 in muscle physiology and disease: lessons from mouse models”, Disease Models & Mechanisms 3:298-303 (2010).
[cited by applicant]
Zhao, Jun , et al., “SIRT1 and exercises”, Chinese Journal of Gerontology, vol. 31, No. 5, published on May 4, 2011, pp. 906-910.
[cited by applicant]
Bauer, “Pharmaceutical solids-the amorphous phase.” Journal of Validation Technology 15.3 (2009): 63.
[cited by applicant]
Extended European Search Report for EP Application No. 22812156.2 dated Apr. 14, 2025.
[cited by applicant]
“International Search Report and Written Opinion for International Application No. PCT/AU2017/051435 mailed Mar. 6, 2018”.
[cited by applicant]
Arany, Zoltan , et al., “HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha”, Nature 451:1008-1012 (Feb. 2018).
[cited by applicant]
Arbiser, Jack L, et al., “Overexpression of VEGF 121 in Immortalized Endothelial Cells Causes Conversion to Slowly Growing Angiosarcoma and High Lebel Expression of the VEGF Receptors VEGFR-1 and VEGFR-2 in Vivo”, Am J …
[cited by applicant]
Askew, Christopher D, et al., “Skeletal muscle phenotype is associated with exercise tolerance in patients with peripheral arterial disease”, J Vasc Surg, 41(5):802-807 (2005).
[cited by applicant]
Baker, Marianne , et al., “Use of the mouse aortic ring assay to study angiogenesis”, Nat Protoc 7(1):89-104 (Dec. 22, 2011).
[cited by applicant]
Baltgalvis, Kristen A, et al., “Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice”, Am J Physiol Heart Circ Physiol 306:H1128-H1145 (Feb. 21, 2014).
[cited by applicant]
Bassel-Duby, Rhonda , et al., “Signaling Pathways in Skeletal Muscle Remodeling”, Annu Rev Biochem 75:19-37 (Feb. 15, 2006).
[cited by applicant]
Blanco, Raquel , et al., “VEGF and notch in tip and stalk cell selection”, Cold Spring Harb Perspect Med 3: a006569 (2013).
[cited by applicant]
Bogan, Katrina L, et al., “Nicotinic acid, nicotinamide, and nicotinamide roboside: A molecuar evaluation of NAD+ precursos vitamins in human nutrition”, Annu Rev Nutr 28:115-130 (Apr. 22, 2008).
[cited by applicant]
Booth, Frank W, et al., “Molecular and cellular adaptation of muscle in response to exercise: perspectives of various models”, Physiol Rev 71(2):541-585 (Apr. 1991).
[cited by applicant]
Borradaile, Nica M, et al., “Nicotinamide Phosphoribosyltransferase Imparts Human Endothelial Cells with Extended Replicative Lifespan and Enhanced Angiogenic Capacity in a High Glucose Environment”, Aging Cells 8:100-1…
[cited by applicant]
Braidy, Nady , et al., “Age related changes in NAD+ metabolism oxidative stress and sirt1 activity in wistar rats”, PLoS One, 6(4):e19194 (Apr. 26, 2011).
[cited by applicant]
Canto, Carles , et al., “The NAD+ Precursor Nicotinamide Riboside Enhances Oxidative Metabolism—and Protects against High-Fat Diet-Induced Obesity”, Cell Metab, 15:838-847 (Jun. 6, 2012).
[cited by applicant]
Cardus, Anna , et al., “SIRT6 protects human endothelial cells from DNA damage, telomere dysfunction, and senescence”, Cardiovasc Res, 97:571-579 (2013).
[cited by applicant]
Cebasek, V , et al., “A novel staining method for quantification and 3D visualisation of capillaries and muscle fibres”, EurJ Histochem, 48(2):151-158 (Apr.-Jun. 2004).
[cited by applicant]
Chalkiadaki, Angeliki , et al., “Muscle-specific SIRT1 Gain-of-Function Increases Slow-Twitch Fibers and Ameliorates Pathophysiology in a Mouse Model of Duchenne Muscular Dystrophy”, PLoS Genet, 10(7):e1004490 (Jul. 17,…
[cited by applicant]
Chang, Linda , et al., “Notch activation promotes endothelial survival through a P13K-Slug axis”, Microvasc Res, 89:80-85 (Jun. 3, 2013).
[cited by applicant]
Chinsomboon, Jessica , et al., “The transcriptional coactivator PGC-1? mediates exercise-induced angiogenesis in skeletal muscle”, Proc Natl Acad Sci, 106(50):21401-21406 (Dec. 15, 2009).
[cited by applicant]
Costa, Carla , et al., “The endothelial-erectile dysfunction connection: An essential update”, J Sex Med, 6:2390-2404 (2009).
[cited by applicant]
De Souza, Natalie , “Primer: Genome editing with engineered nucleases”, Nat Meth, 9(1):27 (Jan. 2012).
[cited by applicant]
Dimmeler, Stefanie , et al., “Endothelial cell apoptosis in angiogenesis and vessel regression”, Circulation Res, 87:434-439 (Aug. 3, 2000).
[cited by applicant]
Duscha, Brian D, et al., “Capillary Density of Skeletal Muscle”, J Am Coil Cardiol, 33(7):1956-1963 (Feb. 10, 1999).
[cited by applicant]
Escande, Carlos , et al., “Flavonoid apigenin is an inhibitor of the NAD+ ase CD38”, Diabetes, 62:1084-1093 (Apr. 2013).
[cited by applicant]
Escudier, Bernard , et al., “Axitinib for the Management of Metastatic Renal Cell Carcinoma”, Drugs R D 11 (2):113-126 (2011).
[cited by applicant]
Firestein, Ron , et al., “The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth”, PLoS One, 3(4):e2020 (Apr. 16, 2008).
[cited by applicant]
Gomes, Ana P, et al., “Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging”, Cell, 155(7):1624-1638 (Dec. 19, 2013).
[cited by applicant]
Grieger, Joshua C, et al., “Adeno-Associated Virus as a Gene Therapy Vector: Vector Development, Production and Clinical Applications”, Advances in Biochemical Engineering/Biotechnology 99:119-145 (Oct. 25, 2005).
[cited by applicant]
Guarani, Virginia , et al., “Acetylation-dependent regulation of endothelial notch signalling by the SIRT1 deacetylase,”, Nature, 473(7346):234-238 (May 12, 2011).
[cited by applicant]
Harasta, Anne E, et al., “Septal Glucagon-Like Peptide I Receptor Expression Determines Suppression of Cocaine-Induced Behavior”, Neuropsychopharmacology, 40:1969-1978 (Mar. 4, 2015).
[cited by applicant]
Hood, David A, “Plasticity in Skeletal, Cardiac, and Smooth Muscle”, J Appl Physiol, 90:1137-1157 (2001).
[cited by applicant]
Kolluru, Gopi Krishna, et al., “Endothelial Dysfunction and Diabetes: Effects on Angiogenesis, Vascular Remodeling, and Wound Healing”, Int J Vasc Med, 918267, 1-30 (2012).
[cited by applicant]
Koni, Pandelakis A, et al., “Conditional Vascular Cell Adhesion Molecule 1 Deletion in Mice: Impaired Lymphocyte Migration to Bone Marrow”, J Exp Med, 193(6):741-753 (Mar. 19, 2001).
[cited by applicant]
Korff, Thomas , et al., “Integration of Endothelial Cells in Multicellular Spheroids Prevents Apoptosis and Induces Differentiation”, J Cell Biol, 143(5):1341-1352 (Nov. 30, 1998).
[cited by applicant]
Kuznetsov, Andrey V, et al., “Analysis of mitochondrial function in situ in permeabilized muscle fibers, tissues and cells”, Nat Protoc, 3(6):965-976 (May 15, 2008).
[cited by applicant]
Lanza, Gaetano Antonio, et al., “Primary Coronary Microvascular Dysfunction”, Circulation, 121:2317-2325 (2010).
[cited by applicant]
Le Couteur, David G, et al., “A Vascular Theory of Aging”, Journal of Gerontology, 65A(10):1025-1027 (Oct. 2010).
[cited by applicant]
Limbourg, Anne , et al., “Evaluation of postnatal arteriogenesis and angiogenesis in a mouse model of hind-limb ischemia”, Nat Protoc, 4(12):1737-1746 (Nov. 5, 2009).
[cited by applicant]
Lin, Jiandie , et al., “Transcriptional co-activator PGC-1alpha drives the formation of slow-twitch muscle fibres”, Nature, 418:797-801 (Aug. 15, 2002).
[cited by applicant]
Massudi, Hassina , et al., “Age-Associated Changes in Oxidative Stress and NAD Metabolism in Human Tissue”, PLoS One, 7(7):e42357 (Jul. 27, 2012).
[cited by applicant]
McCormick, William F, “The Pathology of Vascular (“Arteriovenous”) Malformations”, J Neurosurg 24:807-816 (1966).
[cited by applicant]
Mersmann, Nadine , et al., “Aspartoacylase-LacZ Knockin Mice: An Engineered Model of Canavan Disease”, PLOS One, 6(5):e20336 (May 20, 2011).
[cited by applicant]
Mitchell, Sarah J, et al., “The SIRT1 Activator SRT1720 Extends Lifespan and Improves Health of Mice Fed a Standard Diet”, Cell Reports 6:836-843 (Mar. 13, 2014).
[cited by applicant]
Morscher, Stefan , et al., “Semi-Quantitative Multispectral Optoacoustic Tomography (MSOT) for Volumetric PK Imaging of Gastric Emptying”, Photoacoustics, 2:103-110 (Jun. 18, 2014).
[cited by applicant]
Mouchiroud, Laurent , et al., “NAD+ metabolism, a therapeutic target for age-related metabolic disease”, Crit Rev Biochem Mol Biol, 48(4):397-408 (2013).
[cited by applicant]
Mouchiroud, Laurent , et al., “The NAD+/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial URP and FOXO Signaling”, Cell, 154:430-441 (Jul. 18, 2013).
[cited by applicant]
Muzumdar, Mandar Deepak, et al., “A Global Double-Fluorescent Cre Reporter Mouse”, Genesis, 45:593-605 (Sep. 14, 2007).
[cited by applicant]
Noseda, Michela , et al., “Notch Activation Induces Endothelial Cell Cycle Arrest and Participates in Contact Inhibition: Role of P21Cip1 Repression”, Mob Cell Biol, 24(20):8813-8822 (Oct. 2004).
[cited by applicant]
Dommen, Saji , et al., “Vascular Endothelial Growth Factor A (VEGF-A) Induces Endothelial and Cancer Cell Migration Through Direct Binding to Integrin alpha9beta1”, J Biol Chem, 286(2):1083-1092 (Jan. 14, 2011).
[cited by applicant]
Pearson, Kevin J, et al., “Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction with out extending lifespan”, Cell Metab, 8(2):157-168 (Aug. 2008).
[cited by applicant]
Pette, Dirk , et al., “Myosin isoforms, muscle fiber types, and transitions”, Microsc Res Tech, 50:500-509 (Apr. 2000).
[cited by applicant]
Potente, Michael , et al., “Emerging roles of SIRT1 in vascular endothelial homeostasis”, Cell Cycle 7 (14):2117-2122 (Jul. 15, 2008).
[cited by applicant]
Potente, Michael , et al., “SIRTI Controls Endothelial Angiogenic Functions During Vascular Growth”, Genes & Development 21:2644-2658 (Aug. 23, 2007).
[cited by applicant]
Price, Nathan L, et al., “SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function”, Cell Metab, 15(5):675-690 (May 2, 2012).
[cited by applicant]
Prior, Steven J, et al., “Sacropenia is Associated with Lower Skeletal Muscle Capillarization and Exercise Capacity in Older Adults”, J Gerontol A Biol Sci Med Sci, 71 (8):1096-1101 (Feb. 17, 2016).
[cited by applicant]
Respress, Jonathan L, et al., “Transthoracic Echocardiography in Mice”, Journal of Visualized Experiments 39: e1738 (May 28, 2010).
[cited by applicant]
Rose, Peter , et al., “GYY4137, a Novel Water-Soluble, H25-Releasing Molecule”, Methods in Enzymology, 554:143-167 (2015).
[cited by applicant]
Ross, Jaime M, “Visualization of Mitochondrial Respiratory Function Using Cytochrome C Oxidase/Succinate Dehydrogenase (COX/SDH) Double-Labeling Histochemistry”, J Vis Exp 57:e3266 (Nov. 23, 2011).
[cited by applicant]
Rowe, Glenn C, et al., “Running Forward: New Frontiers in Endurance Exercise Biology”, Circulation 129 (7):798-810 (Feb. 18, 2014).
[cited by applicant]
Sauve, Anthony A, et al., “Sir2 Regulation by Nicotinamide Results from Switching Between Base Exchange and Deacetylation Chemistry”, Biochemistry, 42(31):9249-9256 (Aug. 12, 2003).
[cited by applicant]
Schwartz, Joan P, et al., “The Effect of Growth Conditions on NAD and NADH Concentrations and the NAD: NADH Ratio in Normal and Transformed Fibroblasts”, J Biol Chem, 249(13):4138-4143 (Jul. 1974).
[cited by applicant]
Smith, Julianne , et al., “A combinatorial approach to create artificial homing endonucleases cleaving—chosen sequences”, Nucleic Acids Research, 34(22):e149 (Nov. 27, 2006).
[cited by applicant]
Tan, Wenfang , et al., “Precision Editing of Large Animal Genomes”, Adv Genet, 80:37-97 (2012).
[cited by applicant]
Turner, Nigel , et al., “Enhancement of Muscle Mitochondrial Oxidative Capacity and Alterations in Insulin Action are Lipid Species Dependent”, Diabetes, 58:2547-2554 (Nov. 2009).
[cited by applicant]
Uddin, Golam M, et al., “Head to Head Comparison of Short-Term Treatment with the NAD+ Precursos Nicotinamide Mononucleotide (NMN) and 6 Weeks of Exercise in Obese Female Mice”, Front Pharmacol, 7(258):1-11 (Aug. 19, 20…
[cited by applicant]
Urnov, Fyodor D, et al., “Genome editing with engineered zinc finger nucleases”, Nat Rev Genet 11(9):636-646 (Sep. 2010).
[cited by applicant]
Van Beijnum, Judy R, et al., “Isolation of endothelial cells from fresh tissues”, Nat Protoc, 3(6):1085-1091 (Jun. 5, 2008).
[cited by applicant]
Vasko, Radovan , et al., “Endothelial Sirtuin 1 Deficiency Perpetrates Nephrosclerosis through Downregulation of Matrix Metalloproteinase-14: Relevance to Fibrosis of Vascular Senescence”, J Am Soc Nephrol, 25:276-291 (…
[cited by applicant]
Wang, Pei , et al., “Intracellular NAMPT-NAD+-SIRT1 Cascade Improves Post-Ischaemic Vascular Repair by Modulating Notch Signalling in Endothelial Progenitors”, Cardiovascular Research 104:477-488 (Oct. 23, 2014).
[cited by applicant]
Wang, Gelin , et al., “P7C3 Neuroprotective Chemicals Function by Activating the Rate-Limiting Enzyme in NAD Salvage”, Cell, 158(6):1324-1334 (Sep. 11, 2014).
[cited by applicant]
Wei, Hao , et al., “Aortopathy in a Mouse Model of Marfan Syndrome is Not Mediated by Altered Transforming Growth Factor 13 Signaling”, J Am Heart Assoc, 1-14 (2017).
[cited by applicant]
Wen, Liang , et al., “Ca2+/Calmodulin-Dependent Protein Kinase Kinase Beta Phosphorylation of Sirtuin 1 in Endothelium is Atheroprotective”, Proc Natl Acad Sci, 110:e2420-e2427 (Jun. 10, 2013).
[cited by applicant]
Yamada, Kazuo , et al., “The simultaneous measurement of nicotinamide adenine dinucleotide and related compounds by liquid chromatography/electrospray ionization tandem mass spectrometry”, Analytical Biochemistry, 352:2…
[cited by applicant]
Yang, Guangdong , et al., “H2S and Blood Vessels: An Overview”, P.K. Moore, M. Whiteman (eds.), Chemistry, Biochemistry and Pharmacology of Hydrogen Sulfide, Handbook of Experimental Pharmacology 230 (2015).
[cited by applicant]
Yang, Guangdong , et al., “H2S and Blood Vessels: An Overview”, P.K. Moore, M. Whiteman (eds.), H I Chemistry, Biochemistry and Pharmacology of Hydrogen Sulfide, Handbook of Experimental Pharmacology 230 pp. 85-110 (201…
[cited by applicant]
Yoshino, Jun , et al., “Nicotinamide mononucleotide, a key NAD intermediate, treats the pathophysiology of diet- and age-Induced diabetes in mice”, Cell Metab, 14(4):528-536 (Oct. 5, 2011).
[cited by applicant]
Zhang, Yuan , et al., “Hydrogen Sulfide, the Next Potent Preventive and Therapeutic Agent in Aging and Age-Associated Diseases”, Molecular and Cellular Biology 33(6):1104-1113 (Mar. 2013).
[cited by applicant]
Zhang, Yi , et al., “Liung endothelial HO-i targeting in vivo using lentiviral miRNA regulates apoptosis and autophagy during oxidant injury”, FASEB J, 27:1-18 (Jun. 14, 2013).
[cited by applicant]
Zhu, Chen-Tseh , et al., “A Hydrazine Coupled Cycling Assay Validates the Decrease in Redox Ratio Under Starvation in
[cited by applicant]
ADP PubChem SID 134971804 deposited on Mar. 21, 2012.
[cited by applicant]
Ahmadibeni et al., “Solid-Phase Synthesis of Symmetrical 5′,5′-Dinucleoside Mono-, Di-, Tri-, and Tetraphosphodiesters,” Organic Letters, 9(22): 4483-4486 (2007).
[cited by applicant]
AMP PubChem SID 134970876 deposited on Mar. 21, 2012.
[cited by applicant]
Anastasi et al., “New antiviral nucleoside prodrugs await application,”
[cited by applicant]
Asher et al., “SIRT1 Regulates Circadian Clock Gene Expression through PER2 Deacetylation,” Cell, 134:317 (2008).
[cited by applicant]
Atkinson et al., “Nicotinamide 6-Mercaptopurine Dinucleotide and Related Compounds: Potential Sources of 6-Mercaptopurine Nucleotide in Chemotherapy,” Nature, 196: 35-36 (1962).
[cited by applicant]
ATP PubChem SID 134972915 deposited on Mar. 21, 2012.
[cited by applicant]
Barnea et al., “High-Fat Diet Delays and Fasting Advances the Circadian Expression of Adiponectin Signaling Components in Mouse Liver,” Endicrinology 150:161 (2009).
[cited by applicant]
Bauer, “Polymorphism-A Critical Consideration in Pharmaceutical Development, Manufacturing, and Stability,” Journal of Validation of Technology, 14(5):15-23 (2008).
[cited by applicant]
Bazzanini et al., “Synthetic approaches to a mononucleotide prodrug of cytarabine,” Nucleosides, Nucleotides, and Nucleic Acids, 24(10-12):1635-1649 (2005).
[cited by applicant]
Belenky et al., “Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD+,” Cell, 129(3):473-484 (2007).
[cited by applicant]
Berghaeuser et al., “A Simple Preparation of an Enzyme Reactor Producing Nicotinamidemononucleotide,” Biotechnology Letters, 3(7): 339-344 (1981).
[cited by applicant]
Bieganowski et al., “Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a preiss-handler independent route to NAD+ in fungi and humans,” Cell, 117:495-502 (2004).
[cited by applicant]
Bobeck et al., “Advances in nucleoside monophosphate prodrugs as anti-HCV agents,” Antiviral Therapy—An Official Publication of the International Society for Antiviral Research, 15(7):935-950 (2010).
[cited by applicant]
Bordone et al., “Calorie restriction, SIRT1 and metabolism: understanding longevity,” Nat Rev Mol Cell Biol, 6:298-305 (2005).
[cited by applicant]
Borradaile et al., “NAD+, Sirtuins, and Cardiovascular Disease,” Current Pharmaceutical Design, 15(1):110-117 (2016).
[cited by applicant]
Brittain et al., “X-Ray Diffraction of Pharmaceutical Materials,” Profiles of Drug Substances, Excipients, and Related Methodology, 30:273-319 (2003).
[cited by applicant]
Byrn et al., “Pharmaceutical solids: a strategic approach to regulatory considerations,” Pharmaceut Res, 12(7):945-954 (1995).
[cited by applicant]
Caira., Crystalline Polymorphism of Organic Compounds, Topics in Current Chemistry, 198: 163-208 (1998).
[cited by applicant]
Cardiac Medications, Heart.org, http://www.heart.org/en/health-topics/heart-attack/treatment-of-a-heart-attack/cardiac-medications (2015).
[cited by applicant]
CAS Registry No. 108273-23-0 (1987).
[cited by applicant]
CAS Registry No. 108489-22-1 (1987).
[cited by applicant]
CAS Registry No. 1094-61-7 (1984).
[cited by applicant]
CAS Registry No. 150035-58-8 (1993).
[cited by applicant]
CAS Registry No. 321-02-8.
[cited by applicant]
CAS Registry No. 906748-40-1 (2006).
[cited by applicant]
Cattaneo-Pangrazzi et al., “The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-14…
[cited by applicant]
Cayman Chemical, “Beta-Nicotinamide mononucleotide,” Item No. 16411 Product Information (2014).
[cited by applicant]
Cayman Chemical, “Beta-Nicotinamide Mononucleotide,” Item No. 16411 Safety Data Sheet, Cayman Chemical (2015).
[cited by applicant]
Chemical Cayman, “Nicotinic Acid Mononucleotide,” Item No. 32883.
[cited by applicant]
Cherney, “Osteoarthritis Medications List,” Healthline, https://www.healthline.com/health/osteoarthritis/medications-list#nsaids (2016).
[cited by applicant]
Cho et al., “Efficient synthesis of nucleoside aryloxy phosphoramidate prodrugs utilizing benzyloxycarbonyl protection,” Tetrahedron, 67(30): 14 pages (2011).
[cited by applicant]
Congiatu et al., “Novel potential anticancer naphthyl phosphoramidates of BVdU: separation of diastereoisomers and assignment of the absolute configuration of the phosphorus center,” Journal of medicinal chemistry, 49(2…
[cited by applicant]
Corda et al., “Functional aspects of protein mono-ADP-ribosylation,” EMBO J, 22(9):1953-1958 (2003).
[cited by applicant]
Cross et al., “Rules for the Nomenclature of Organic Chemistry. Section E: Sterohemistry,” Pure Appl Chem, 45(1):11-30, (1976).
[cited by applicant]
Das et al., “Nicotinamide mononucleotide, an NAD+ precursor, reverses age-associated decline in exercise capacity byincreasing skeletal muscle capillary density in a Sirt1-dependent manner.”: 2015 Hobart Programme, Nov.…
[cited by applicant]
Database Registry Chemical Abstracts, Database Accession No. 807266-77-9, CAS Registry No. 807266-77-9 (Jan. 2, 2005).
[cited by applicant]
Dekker, Polymorphism in Pharmaceutical Solids, First Ed, pp. 184-208 (1999).
[cited by applicant]
Dekker, Polymorphism in Pharmaceutical Solids, First Ed, pp. 7-8 (1999).
[cited by applicant]
Diabetes Treatment, Drugs.com, https://www.drugs.com/diabetes-treatment.html (2018).
[cited by applicant]
Dowden et al., “Chemical Synthesis of the Novel CA 2+ Messenger NAADP,” Nucleosides, Nucleotides and Nucleic Acids, 24(5-7):513-518 (2005).
[cited by applicant]
Eliseev et al., “Comparative study of antihypoxic properties of some nucleosides and nucleotides.”
[cited by applicant]
Erion et al., “Design, Synthesis, and Characterization of a Series of Cytochrome P450 3A-Activated Prodrugs (HepDirect Prodrugs) Useful for Targeting Phosph(on)ate-Based Drugs to the Liver,” JACS Articles, 126: 5154-516…
[cited by applicant]
Extended European Search Report for EP Application No. 16833957.0 dated Dec. 21, 2018.
[cited by applicant]
Extended European Search Report for EP Application No. 16852711.7 dated Feb. 11, 2019.
[cited by applicant]
Extended European Search Report for EP Application No. 23197016.1 dated Oct. 18, 2023.
[cited by applicant]
Fang et al., “Defective Mitophagy in XPA via PARP-1 Hyperactivation and NAD+/SIRT1 Reduction,” Cell, 157(4):882-896 (2014).
[cited by applicant]
Galli et al., “The Nicotinamide Phosphoribosyltransferase: A Molecular Link between Metabolism, Inflammation, and Cancer”, Cancer Research, 70(1), pp. 8-11, 2010.
[cited by applicant]
Garten et al., “Nampt: Linking NAD biology, metabolism, and cancer,” Trends Endocrinol Metab, 20(3):130-138 (2009).
[cited by applicant]
Gavande et al., “DNA repair targeted therapy: The past or future of cancer treatment?,” Pharmacology & Therapeutics, 160:65-83 (2016).
[cited by applicant]
Gockel et al., “Synthesis of an oligonucleotide with a nicotinamide mononucleotide residue and its molecular recognition in DNA helices,” Organic & Biomolecular Chemistry, 13(41):10303-10309 (2015).
[cited by applicant]
Guest et al., “Changes in Oxidative Damage, Inflammation and [NAD(H)] with Age in Cerebrospinal Fluid,” PLOS One, 9(1):e85335 (2014).
[cited by applicant]
Hardie, “Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status”,
[cited by applicant]
Harrison et al., “Inhibition of Platelet Aggregation and the Platelet Release Reaction by alpha, omega Diadenosine polyphosphates,” FEBS Letts 54(1):57-60 (1975).
[cited by applicant]
Hecker et al., “Prodrugs of Phosphates and Phosphonates,” Journal of Medicinal Chemistry, 51(8):2328-2345 (2008).
[cited by applicant]
Hirayama, Yuukikagoubutsu Kessyo sakusei Handbook—Genri to Know-how—(Handbook for Preparation of Crystals of Organic Compounds—Principle and Know-how—), Maruzen Co. Ltd., pp. 37-84 (2008).
[cited by applicant]
Huang et al., “Metabolomics-driven identification of adenosine deaminase as therapeutic target in a mouse model of Parkinson's disease,” Journal of Neurochemistry, 150: 282-295 (2019).
[cited by applicant]
Imai et al., “Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase,” Nature, 403:795-800 (2000).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2016/045855 dated Nov. 14, 2016.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2016/054776 dated Jan. 25, 2017.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/015672 dated May 15, 2019.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/023318 dated Jun. 24, 2020.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US22/31124 dated Oct. 6, 2022.
[cited by applicant]
Invitation to Pay Additional Fees for International Application No. PCT/US22/31124 dated Aug. 5, 2022.
[cited by applicant]
Kamel et al., “Pharmaceutical significance of cellulose: A review”, Express Polym Letters 2(11): 758-778 (2008).
[cited by applicant]
Kohsaka et al., “high-Fat Diet Disrupts Behavioral and Molecular Circadian Rhythms in Mice,” Cell Metab, 6:414 (2007).
[cited by applicant]
Lee et al., “A Chemical Synthesis of Nicotinamide Adenine Dinucleotide (NAD+),” Chemical Communications (Cambridge), 8: 729-730 (1999).
[cited by applicant]
Lee, “A practical guide to pharmaceutical polymorph screening & selection,” Asian Journal of Pharmaceutical Science 9(4): 163-175 (2014).
[cited by applicant]
Leisvuori et al. “5′, 5′-Phosphodiesters and esterase labile triesters of 2′-C methylribonucleosides”, ARKIVOC: Online Journal of Organic Chemistry (2012).
[cited by applicant]
Lin et al., “Nicotinamide adenine dinucleotide, a metabolic regulator of transcription, longevity and disease,” Curr Opin Cell Biol, 15:241-246 (2003).
[cited by applicant]
Liu et al., “A Novel Preparation of Nicotinamide Mononucleotide,” Nucleosides & Nucleotides, 13(5): 1215-1216 (1994).
[cited by applicant]
Liu et al., “Enzymatic synthesis of polymers containing nicotinamide mononucleotide,” Nucleic Acids Research, 23(18):3742 (1995).
[cited by applicant]
Liu et al., “Synthesis of Phosphodiester-type Nicotinamide Adenine Dinucleotide Analogs,” Tetrahedron, 65(40): 8378-8383 (2009).
[cited by applicant]
Makarov et al., “Syntheses and chemical properties of B-nicotinamide riboside and its analogues and derivatives,” Beilstein J Org Chem, 15: 401-430 (2019).
[cited by applicant]
McGuigan et al., “Certain phosphoramidate derivatives of dideoxy uridine (ddU) are active against HIV and successfully by-pass thymidine kinase,” FEBS Letters, 351: 11-14 (1994).
[cited by applicant]
McGuigan et al., “Phosphorodiamidates as a Promising New Phosphate Prodrug Motif for Antiviral Drug Discovery: Application to Anti-HCV Agents,” Journal of Medicinal Chemistry, 54: 8632-8645 (2011).
[cited by applicant]
Medications for Dermatitis, Drugs.com, https://www.drugs.com/condition/dermatitis.html (2018).
[cited by applicant]
Medications for Obesity, Drugs.com, https://www.drugs.com/condition/obesity.html (2018).
[cited by applicant]
Medications for Peripheral Neuropathy, Drugs.com, https://www.drugs.com/condition/peripheral-neuropathy.html (2018).
[cited by applicant]
Medications for Thrombotic/Thromboembolic Disorder, Drugs.com, https://www.drugs.com/condition/thrombotic-thromboembolic-disorder.html (2018).
[cited by applicant]
Menissier de Murcia et al., “Functional Interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse,” EMBO J, 22(9):2255-2263 (2003).
[cited by applicant]
Migaud et al., “Probing Aplysia californica Adenosine 5′-Diphosphate Ribosyl Cyclase for Substrate Binding Requirements: Design of Potent Inhibitors,” Biochemistry, 38:9105-9114 (1999).
[cited by applicant]
Mikhailopulo et al., “Synthesis of glycosides of nicotinamide and nicotinamide mononucleotide,” Synthesis, 5:388-389 (1981).
[cited by applicant]
Moazed, “Enzymatic activities of Sir2 and chromatin silencing,” Curr Opin Cell Biol, 13(2):232-238 (2001).
[cited by applicant]
Montgomery et al., “Synthesis of Potential Anticancer Agents. XXVIII. Simple Esters of 6-Mercaptopurine Ribonucleotide2,” The Journal of Organic Chemistry, 26(6):1929-1933 (1961).
[cited by applicant]
Moynihan et al., “Increased dosage of mammalian Sir2 in pancreatic β cells enhances glucose-stimulated insulin secretion in mice,” Cell Metab, 2:105-117 (2005).
[cited by applicant]
Nakahata et al., “The NAD+-Dependent Deacetylase SIRT1 Modulates CLOCK-Mediated Chromatin Remodeling and circadian Control,” Cell, 134(2):329 (2008).
[cited by applicant]
Nakai et al., Shin Seizaigaku (New Pharmacy), Nanzando Co. Ltd., 1st Edition, 2nd Printing, pp. 102-104, 217-236 (1984).
[cited by applicant]
Nikiforov et al., “Pathways and Subcellular Compartmentation of NAD Biosynthesis in Human Cells,” The Journal of Biological Chemistry, 286 (24): 21767-21778 (2011).
[cited by applicant]
Park et al., “Nicotinamide Ribose 5′-0-[S-(3-Bromo-2-oxopropyl)] thiophosphate: A New Affinity Label for NMN Sites in Enzymes,” Archives of Biochemistry and Biophysics, 303(2):483-488 (1993).
[cited by applicant]
Pencina et al., “MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of Beta-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Old…
[cited by applicant]
Pencina et al., “Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study”, The Journal of Clinical Endocrinology & Metabolism, Feb. 6, 2023, 00, pp. 1-13.
[cited by applicant]
Pertusati et al., “Medicinal chemistry of nucleoside phosphonate prodrugs for antiviral therapy,” Antivir Chem Chemother, 22(5):181-203 (2012).
[cited by applicant]
Petrelli et al., “NMN/NaMN Adenylyltransferase (NMNAT) and NAD Kinase (NADK) Inhibitors: Chemistry and Potential Therapeutic Applications,” Current Medicinal Chemistry, 18: 1973-1992 (2011).
[cited by applicant]
Pfleiderer et al., “Zum Wirkungsmechanismus von Dehydrogenasen V. Uber die Bedeutung des Adenosindiphosphatrestes im Nicotinamid-Adenin-Dinucleotid,” Biochimica et Biophysica Acta, 73:39-49 (1963).
[cited by applicant]
Pfleiderer et al., “Zum Wirkungsmechanismus von Dehydrogenasen. Das Reaktionsverhalten von Pyridinnucleotiden (PN) und PN-Modellen mit Sulfit als nucleophilem Agens,” Chemische Berichte, 93(12):3083-3099 (1960).
[cited by applicant]
Picard et al., “Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-γ,” Nature, 429:771-776 (2004).
[cited by applicant]
Preitner et al., “The Orphan Nuclear Receptor REV-ERBa Controls Circadian Transcription within the Positive Limb of the Mammalian circadian Oscillator,” Cell, 110:251 (2002).
[cited by applicant]
PubChem SID: 347731451 “Substance Record 321-02-8” retrieved online <https://pubchem.ncbi.nlm.nih.gov/substance/347731451>: 6 pages (Create Date Oct. 23, 2017).
[cited by applicant]
Puech et al., “Nucleotidic prodrugs of anti-HIV dideoxynucleosides”, Bioorganic & medicinal chemistry letters 2(6): 603-606 (1992).
[cited by applicant]
Rajman et al., “Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence,” Cell Metabolism, 27(3): 529-547 (2018).
[cited by applicant]
Ramsey et al., “Cicadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis,” Science, 324(5927):651-654 (2009).
[cited by applicant]
Redpath et al., “Nicotinamide Benzimidazolide Dinucleotides Non-Cyclisable Analogues of NAD+,” Synlett, 25:2331-2336 (2014).
[cited by applicant]
Riemschneider et al., “Zur Beeinflussung von Stoffwechselvorgangcn durch unphysiologische Verbindungen, IV: Nicotinylaminosaureester und Nucleosid-Deritvate,” Insect repellent science, 41(3):99-106 (1976).
[cited by applicant]
Rodgers et al., “Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1,” Nature, 434:113-118 (2005).
[cited by applicant]
Rodionova et al., “Metabolic and bactericidal effects of targeted suppression of NadD and NadE enzymes in mycobacteria,” mBio, 5(1):e00747-13 (2014).
[cited by applicant]
Roskar et al., “Analytical Methods for Quantification of Drug Metabolites in Biological Samples,” IntechOpen, Chapter 4:79-126 (2012).
[cited by applicant]
Rudic et al., “BMAL1 and CLOCK, Two Essential Components of the Circadian Clock, Are Involved in Glucose Homeostasis,” PLoS Biol, 2:e377 (2004).
[cited by applicant]
Rutter et al., “Regulation of Clock and NPAS2 DNA Binding by the Redox State of NAD Cofactors,” Science, 293(5529):510 (2001).
[cited by applicant]
Sarma et al., “Investigations of Inter- and Intramolecular Interactions in Flavin-Adenine Dinucleotide by Proton Magnetic Resonance,” Biochemistry, 7(12):4359-4367 (1968).
[cited by applicant]
Sato et al., “A Functional Genomics Strategy Reveals Rora as a Component of the Mammalian Circadian Clock,” Neuron, 43:527 (2004).
[cited by applicant]
Sharma et al., “X-ray diffraction: a powerful method of characterizing nanomaterials,” Recent Research in Science and Technology, 4:77-79 (2012).
[cited by applicant]
Shioji, Kokei Seizai no Seizo Gijutsu (Manufacture Technology of Solid Tablet), CMC Publishing Co. Ltd., Popular Edition, 1st Printing, pp. 9-14 (2003).
[cited by applicant]
Sleep Disorders: Medications for Circadian Rhythm Disorders, WebMD, https://www.webmd.com/sleep-disorders/circadian-rhythm-disorder-medications#1 (2018).
[cited by applicant]
Smith et al., “A phylogenetically conserved NAD+-dependent protein decetylase activity in the Sir2 protein family,” Proc Natl Acad Sci, 97(12):6658-6663 (2000).
[cited by applicant]
Soto-Gamez et al., “Therapeytic interventions for aging: the case of cellular senescence,” Drug Discovery Today, 22(5):786-795 (2017).
[cited by applicant]
Stein et al., “Expression of nampt in hippocampal and cortical excitatory neurons is critical for cognitive function,” J Neurosci, 34(17): 5800-5815 (2014).
[cited by applicant]
Stein et al., “Scientific ablation on Nampt in adult neural stem cells recapitulates their functional defects during aging,” EMBO J, 33(12):1321-1340 (2014).
[cited by applicant]
Stieger et al., “7: Recrystallization of Active Pharmaceutical Ingredients,” Crystallization—Science and Technology, 183-204 (2012).
[cited by applicant]
Takada, “API form screening and selection in drug discovery stage”, Pharm Stage, 6(10):20-25. (2007).
[cited by applicant]
Takahashi et al., “The Genetics of Mammalian Circadian Order and Disorder: Implications for Physiology and Disease,” Nat Rev Genet, 9(10):764 (2008).
[cited by applicant]
The Chemical Society of Japan Ed., 4th Edition Jikken Kagaku Kouza 1 Kihon Sousa I (4th Edition Experimental Chemistry 1 Basic Operation I), Maruzen Co. Ltd., 2nd Printing, pp. 184-186 (1996).
[cited by applicant]
Thorpe et al., “Lipoamide Dehydrogenase from Pig Heart. Pyridine Nucleotide Induced Changes in Monoalkylated Two-Electron Reduced Enzyme,” Biochemistry, 20: 1507-1513 (1981).
[cited by applicant]
Turek et al., “Obesity and Metabolic Syndrome in Circadian Clock Mutant Mice,” Science, 308:1043 (2005).
[cited by applicant]
United States Department of Health and Human Services. “Guidance for Industry Pyrogen and Endotoxin Testing: Questions and Answers,” pp. 1-10 (2012).
[cited by applicant]
United States Pharmacopeia General Chapter <151> Pyrogen Test, 2 pages.
[cited by applicant]
Walt et al., “An Efficient Chemical and Enzymatic Synthesis of Nicotinamide Adenine Dinucleotide (NAD+),” Journal of the American Chemical Society, 106(1): 234-239 (1984).
[cited by applicant]
Wang et al., “A local mechanism mediates NAD-dependent protection of axon degeneration,” J Cell Biol, 170(3):349-355 (2005).
[cited by applicant]
Wiemer et al., “Prodrugs of Phosphnates and Phosphates: Crossing the Membrane Barrier,” Topics in Current Chemistry, 360:115-160 (2014).
[cited by applicant]
Woenckhaus, “Synthesen und biochemische Eigenschaften wassertoffubertragender Coenzye modelle,” Chemische Berichte, 97(9):2439-2446 (1964).
[cited by applicant]
Wound Care Medications, GoodRx.com, https://www.goodrx.com/wound-care/drugs (2018).
[cited by applicant]
Yamamoto et al., “Nicotinamide mononucleotide, an intermediate of NAD+ synthesis, protects the heart from ischemia and reperfusion”, PloS one 9.6: e98972 (2014).
[cited by applicant]
Yang et al., “NAD+-dependent Deacetylase SIRT3 Regulates Mitochondrial Protein Synthesis by Deacetylation of the Ribosomal Protein MRPL10,” J Biol Chem, 285:7417-7429 (2010).
[cited by applicant]
Ho et al., “Fertility protection during chemotherapy treatment by boosting the NAD (P)+ metabolome.” EMBO Molecular Medicine 16 (2024): 2583-2618.
[cited by applicant]
Pencina et al., “Nicotinamide adenine dinucleotide augmentation in overweight or obese middle-aged and older adults: a physiologic study.” The Journal of Clinical Endocrinology & Metabolism 108 (2023): 1968-1980.
[cited by applicant]
Pencina et al., “MIB-626, an oral formulation of a microcrystalline unique polymorph of β-nicotinamide mononucleotide, increases circulating nicotinamide adenine dinucleotide and its metabolome in middle-aged and older …
[cited by applicant]
Pencina et al., “Oral MIB-626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID-19 and Acute Kidney Injury: A Randomized Controlled Trial.” …
[cited by applicant]
Perry et al., “NAD+ precursors prolong survival and improve cardiac phenotypes in a mouse model of Friedreich's Ataxia.” JCI Insight 9(16) (2024): e177152.
[cited by applicant]
Sands et al., “Assessing colonic exposure, safety, and clinical activity of SRT2104, a novel oral SIRT1 activator, in patients with mild to moderate ulcerative colitis.” Inflammatory Bowel Diseases 22(3) (2016): 607-614.
[cited by applicant]
Valderrabano et al., “Dysregulated nicotinamide adenine dinucleotide metabolome in patients hospitalized with COVID-19.” Aging Cell 23 (2024): e14326.
[cited by applicant]